RAPID MICRO BIOSYSTEMS, INC. Q3 FY2024 earnings call

• Third quarter total revenue increased 24% to a quarterly record, marking eighth consecutive quarter exceeding guidance. Reaffirming full-year 2024 revenue outlook of at least $27 million.
• Placed 7 growth direct systems in Q3, 15 total in 2024, 156 total placed systems. Had a multi-system order from a top pharma customer as part of global rollout, exemplifying land and expand strategy.
• Achieved positive 8% gross margins in Q3, a 35-percentage point improvement year over year. Cost structure improvements driving gross margin expansion.
• Continued expansion of Rapid Sterility commercial launch through conferences, webinars, and on-site demos, with positive feedback on the value proposition.
• Goal to achieve positive cash flow by end of 2027 without additional financing, with strong fundamentals including differentiated product, customer value proposition, and multiple revenue streams.

Third quarter total revenue increased 24% to $7.6 million compared to Q3 last year. Product revenue (systems and consumables) increased 25% to $5.3 million, with systems revenue up almost 50% due to higher system placements and consumable revenue growing in the mid-single digits. Service revenue increased 21% to $2.3 million. Product margins were near breakeven at negative 1% but improved 34 percentage points, while service margins were positive $0.7 million or 29% compared to negative $0.1 million or -7% in Q3 last year. Combined third quarter gross margin was positive 8% compared to negative 27% in Q3 last year, a 35-percentage point improvement. Revenue contribution: Total revenue at $7.6 million, with product and service segments contributing as described.

• Reaffirm full-year 2024 revenue outlook of at least $27 million. Expect Q4 revenue relatively consistent with Q3 due to timing of orders and shipments but room for upside.
• Anticipate gross margins to increase sequentially in Q4, with product margins potentially positive and service margins higher.
• Full-year 2024 operating expenses expected between $50-51 million, with savings from efficiency program offset by one-time severance and other expenses. End Q3 with approximately $61 million in cash and investments.

• Statements made during the call are forward-looking and subject to risks and uncertainties detailed in SEC filings. Factors like new information, future events, or other factors could materially affect actual results.

Q: Brendan Smith asks about Q4 placements and trends into 2025.

A: Sean Wirtjes says the guide is prudent with potential upside, noting elongated purchasing cycles and customer scrutiny but room for upside; Rob Spignesi mentions compelling ROI projects are prioritized.

Q: Dan Arias asks about expectations for accounts in new modalities.

A: Rob Spignesi says uptake is strong in biologics and cell/gene therapies, with funnel driven by large and mid-size biopharma and CDMOs, and Rapid Sterility reinforcing the funnel.

Q: Dan Arias asks about product margins going forward.

A: Sean Wirtjes says on the right trajectory, mix and volume important, with systems having higher gross margin than consumables, and expecting product margins to be positive quarterly in the near term as volumes increase and cost efficiencies continue.